Another study limitation is that blood lipid levels were not measured as part of routine biochemistry for managing patients with SCLC, which would have unblinded the trial, and we did not secure funds to measure cholesterol and other relevant markers from stored samples; therefore, we are unable to correlate these or other factors, such as HMG-CoA reductase levels, in tumor biopsies with outcomes at present. Here, HMGCR is linked to neoplasm.